Gram-Negative Bacterial Infection Market to Record Ascending Growth by 2025 | Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
Get Sample Copy of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=94
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection market. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the gram-negative bacterial infection market.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms.
A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Request TOC of the Report @ www.tmrresearch.com/sample/sample?flag=T&rep_id=94
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial infection market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, gram-negative bacterial infection market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market.
Some of the key players in the gram-negative bacterial infection market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
3739 Balboa St # 1097,
San Francisco, CA 94121
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gram-Negative Bacterial Infection Market to Record Ascending Growth by 2025 | Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd. here
News-ID: 1750720 • Views: 744
More Releases from TMR Research
IoT Engineering Services Market Real Time Analysis & Forecast 2017 - 2025
Global IoT Engineering Services Market: Snapshot The global market for IoT engineering services has been expanding alongside the increasing relevance of IoT across industries and organizations. Internet of Things (IoT) is a wide area of operations that has enabled the streamlining of business processes and reduction of several undue hassles. The growth of IoT over the past decade has been commendable and the services offered by IoT have surfaced as the
Online Collectible Sale Market 2025 | Heritage Auctions Inc., Global Auctions Co …
Global Online Collectible Sale Market: Snapshot Online collectible sale involves selling valuable items on aggregator sites or to independent buyers on the World Wide Web. Collectibles owned over a period or passed down from generation to generation carry high value and that were traditionally bought by jewelers, antique retailers, and specialty stores. In the age of online retailing for clothes to electronics to cars to travel tickets, collectibles and valuables are
Scope Assessment 2025: Water Purifier Market | GE Corporation, Pentair Residenti …
Global Water Purifier Market: Snapshot The global water purifier market is anticipated to testify the stand out dominance of new product launch in the vendor landscape as players constantly look to grab a major share while gaining a competitive edge over their challengers. Bluewater Group’s three new products launched in 2016 were deemed to help the company to strengthen its foothold in the market and attract more consumers. All of the
Online Shopping Market Higher Growth Rate & Forecast 2017 - 2025 | Alibaba, Wal- …
Global Online Shopping Market: Snapshot Online shopping is the act of purchasing goods or services over the Internet. Over the years, online shopping has grown in popularity as people find it convenient to shop from the comfort of their home or office. Online shopping transactions can be completed using credit card, debit card, or e-wallet among others. Internet banking can also be used to complete a transaction for online shopping. Get Sample
More Releases for Infection
Shigella Infection (Shigellosis) Therapeutics- Pipeline Analysis 2018
Shigella infection, also known as shigellosis, is a bacterial infection caused by a family of bacteria known as shigella. The main symptom of this infection is diarrhea, and can be passed through direct contact with the bacteria in the stool. Download the sample report @ https://www.pharmaproff.com/request-sample/1072 The other sign and symptoms associated with shigella infection are abdominal pain, cramps, and fever. Children between the age of two and four years are
Infection Prevention and Control
Infection control products and accessories aids in the prevention and control of hospital associated & other healthcare infections. These products range from disinfectants to sterilization equipment used in the healthcare settings. Infections needs to be controlled while injecting the drugs, during the surgery and hospital stay of a patient. In addition, infection control and preventive measures aid to avoid the most common hospital infections among the healthcare staff. Get Free 10
Gram-Negative Bacterial Infection Market - Infection-type Segmentation 2017 - 20 …
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the
Infection Surveillance Solutions Market
Infection surveillance solution helps healthcare facilities in reporting patient-associated data to the state and federal authorities. Integration of infection surveillance software with already existing networks of medical facilities and hospitals is an easy process. A recent report published by Persistence Market Research (PMR) estimates the global infection surveillance solution market to register a staggering 14.04% CAGR during the forecast- 2017 to 2025. The US$ 316.67 Mn market is likely to
Enteric Disease Testing Market (Amebiasis, C.difficile Infection, Campylobacteri …
"The Report Enteric Disease Testing Market (Amebiasis, C.difficile Infection, Campylobacteriosis, Cholera, Cryptosporidiosis, E.coli Infection, Giardiasis, H.pylori Infection, Norovirus Infection, Rotavirus Infection, Salmonellosis and Shigellosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Infectious enteric diseases are usually caused by a variety of bacteria, viruses and parasites when they enter
Global HIV Infection Pipeline Analysis
The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have